BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oritavancin: Phase III start

The Medicines Co. received SPAs for the planned, double-blind Phase III SOLO-1 and SOLO-2 trials to compare 1,200 mg IV oritavancin vs. IV Vancocin vancomycin. The trials, which are expected to start by...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >